Bristol-Myers Squibb Company's Stock Analysis

Bristol-Myers Squibb Shareholder Votes and Director Elections

Shareholders of Bristol-Myers Squibb elected all 11 nominees to the board of directors, who will serve until the 2027 Annual Meeting. Additionally, the advisory vote on executive compensation and the 2026 stock award and incentive plan were both approved.

The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 was ratified. However, a shareholder proposal to require that the chairperson of the board be an independent director was not approved.

May 08, 2026 16:10:44

Bristol Myers Squibb Reports Q1 2026 Financial Results

Bristol Myers Squibb reported first-quarter revenues of $11.5 billion for 2026, marking a 3% increase compared to the same period in 2025. The Growth Portfolio, which includes key products like Camzyos and Breyanzi, saw a revenue increase of 12%. However, the Legacy Portfolio experienced a revenue decline of 6%, primarily due to generic competition affecting its established products. The company reported GAAP earnings per share of $1.31 and non-GAAP earnings per share of $1.58, reflecting the impacts of certain charges and licensing income.

The company reaffirmed its financial guidance for 2026, expecting total revenues to be between $46.0 billion and $47.5 billion, with non-GAAP earnings per share projected to range from $6.05 to $6.35. Bristol Myers Squibb emphasized its focus on advancing its product pipeline and maintaining operational execution to drive long-term growth. The company also highlighted an increase in research and development expenses, reflecting its commitment to innovation in treating serious diseases.

Apr 30, 2026 07:01:58

Bristol-Myers Squibb Reports Q4 and Full-Year 2025 Results

Bristol-Myers Squibb Company reported its financial results for the fourth quarter and full year of 2025. The fourth quarter revenues increased by 1% to $12.5 billion, with Growth Portfolio revenues rising 16% to $7.4 billion. The company reported a GAAP earnings per share (EPS) of $0.53 and a non-GAAP EPS of $1.26, both figures reflecting a net impact from acquired in-process research and development charges. For the full year, total revenues were $48.2 billion, with a GAAP EPS of $3.46 and a non-GAAP EPS of $6.15. The company also declared an increased quarterly dividend of $0.63 per share, marking the 17th consecutive annual increase in dividends.

For 2026, Bristol-Myers Squibb provided revenue guidance of approximately $46.0 billion to $47.5 billion, anticipating a decline in its Legacy Portfolio revenues by 12-16%, which is expected to be partially offset by continued strength in the Growth Portfolio. The company continues to focus on its immuno-oncology portfolio and has made significant investments in research and development. Additionally, a collaboration with Microsoft was announced to enhance early detection of lung cancer, indicating ongoing commitment to innovation and addressing unmet medical needs.

Feb 05, 2026 07:07:45

Bristol-Myers Squibb Investor Presentation Highlights Growth and Pipeline

On January 12, 2026, Bristol-Myers Squibb posted an investor presentation outlining its growth strategy and pipeline developments. The company reported a 17% increase in sales from its Growth Portfolio, with four assets generating over $1 billion annually. The presentation emphasized advancements in key pipeline programs targeting serious diseases, including therapies for various cancers, cardiovascular conditions, and neurodegenerative diseases. The company aims to strengthen its long-term growth through strategic business development and productivity initiatives, including the integration of AI for operational efficiency.

Bristol-Myers Squibb highlighted its commitment to delivering industry-leading sustainable growth into the 2030s through rigorous execution of its research and development strategy. The company plans to invest in high-potential assets and programs while maintaining a disciplined approach to capital allocation. Over the past three years, Bristol-Myers Squibb has returned approximately $14.5 billion in dividends and $8 billion in share repurchases, demonstrating its financial strength and shareholder-friendly policies.

Jan 12, 2026 10:20:51

Bristol Myers Squibb Announces Tender Offer Results and Amendments

Bristol Myers Squibb has completed the early participation results for its cash tender offers to purchase outstanding notes, as announced on November 17, 2025. The company has adjusted the maximum purchase prices for both Pool 1 and Pool 2 Notes, with the Amended Pool 1 Maximum set to accommodate all validly tendered Pool 1 Notes and the Amended Pool 2 Maximum increased to accept all validly tendered Pool 2 Notes with priority levels 1 through 4, along with a portion of the 2033 Notes. The Offers are set to expire on December 3, 2025, unless extended or terminated earlier, and all conditions of the Offers were satisfied by the Early Tender Deadline.

Bristol Myers Squibb has accepted all validly tendered Pool 1 Notes and Pool 2 Notes with priority levels 1 through 4, eliminating the need for proration for these categories. However, the acceptance of the 2033 Notes will be prorated due to the total amount exceeding the limit. Holders of the accepted Notes will receive cash payments for the total consideration, which will exclude interest accrued after the Early Settlement Date of November 20, 2025. All accepted Notes will be canceled and retired, ceasing to be outstanding obligations of the company.

Nov 18, 2025 16:41:56

Bristol-Myers Squibb Announces €5.0 Billion Notes Offering

Bristol-Myers Squibb Company, through its subsidiary BMS Ireland Capital Funding Designated Activity Company, has completed a public offering of €5.0 billion in various series of notes. The notes include amounts due from 2030 to 2055, with interest rates ranging from 2.973% to 4.581%. The offering is fully guaranteed by Bristol-Myers Squibb on a senior unsecured basis and is governed by an Indenture that includes customary covenants and restrictions.

The proceeds from this offering, along with approximately $3.0 billion in cash on hand, will be used primarily to fund a tender offer for the purchase of outstanding notes and cover associated fees and expenses. Any remaining funds will be allocated for general corporate purposes. The terms of the offering and the notes are detailed in the Prospectus Supplement and the Indenture documents filed with the SEC.

Nov 10, 2025 16:06:36

Bristol-Myers Squibb Announces $7 Billion Cash Tender Offers

Bristol-Myers Squibb Company has initiated cash tender offers to purchase certain outstanding notes for a total purchase price of up to $7 billion. The offers are categorized into two pools: Pool 1, with a maximum of $4 billion, and Pool 2, with a maximum of $3 billion. The tender offers will expire on December 3, 2025, unless extended or terminated. Holders of the notes have the option to receive Total Consideration if they tender their notes by the Early Tender Deadline of November 17, 2025.

The company plans to finance the tender offers through a new debt securities offering, alongside approximately $3 billion in cash on hand. The acceptance of notes will be prioritized based on specific criteria, and accepted notes will be canceled, ceasing to be outstanding obligations. Additionally, the company retains the right to amend, extend, or terminate the offers, and may redeem any remaining notes after the tender process. Investors are encouraged to review the Offer to Purchase for detailed instructions and terms.

Nov 03, 2025 06:09:11

Bristol Myers Squibb Reports Q3 2025 Financial Results and Guidance

Bristol Myers Squibb reported third quarter revenues of $12.2 billion, reflecting a 3% increase compared to the same period in 2024. The Growth Portfolio revenues rose 18% to $6.9 billion, driven primarily by its immuno-oncology products. However, Legacy Portfolio revenues decreased by 12% to $5.4 billion, impacted by generic competition. The company reported GAAP earnings per share (EPS) of $1.08 and non-GAAP EPS of $1.63, which includes a net impact from Acquired IPRD charges and licensing income. Additionally, Bristol Myers Squibb has raised its full-year revenue guidance to a range of approximately $47.5 billion to $48.0 billion and updated its non-GAAP EPS range to $6.40 to $6.60, factoring in the impact of these charges.

In October 2025, Bristol Myers Squibb announced a definitive agreement to acquire Orbital Therapeutics, which includes a promising RNA immunotherapy candidate. This acquisition aligns with the company's strategy to enhance its pipeline and expand therapeutic applications. The transaction is expected to close in the fourth quarter of 2025, subject to customary conditions. The company also noted an increase in expected income from royalties and licensing for the year, further contributing to its revised financial outlook.

Oct 30, 2025 07:09:00

Bristol-Myers Squibb Reports Q2 2025 Financial Results and Guidance

Bristol-Myers Squibb Company reported second-quarter revenues of $12.3 billion for 2025, reflecting a 1% increase compared to the same period in 2024. The Growth Portfolio generated $6.6 billion in revenue, an 18% increase, while the Legacy Portfolio saw a 14% decline to $5.7 billion. The company's GAAP EPS was reported at $0.64, with non-GAAP EPS at $1.46, both figures impacted by a charge related to a strategic partnership with BioNTech. The company has raised its 2025 revenue guidance to between $46.5 billion and $47.5 billion, along with an updated non-GAAP EPS range of $6.35 to $6.65, which accounts for the aforementioned charge.

In addition to its financial results, Bristol-Myers Squibb announced several strategic partnerships aimed at enhancing its product pipeline. Notably, the company has entered into a co-development agreement with BioNTech for a bispecific antibody targeting solid tumors and licensed rights for a prostate cancer therapeutic to RayzeBio, a subsidiary of Bristol-Myers. The company is also creating a new biopharmaceutical entity focused on autoimmune diseases with Bain Capital. These initiatives suggest a focus on expanding their therapeutic offerings and addressing unmet medical needs, which may influence future performance.

Jul 31, 2025 07:06:45

Bristol Myers Squibb Announces Leadership Changes in Development Team

Bristol Myers Squibb Company has announced that Dr. Samit Hirawat, the Chief Medical Officer and Head of Development, will transition to an advisory role effective August 1, 2025, and will leave the company by November 1, 2025. In connection with his departure, Dr. Hirawat will receive severance benefits, pro-rated equity awards, and an annual incentive payout for 2025. The company has expressed gratitude for his contributions over the past six years, during which he played a key role in advancing the company’s drug development efforts.

Cristian Massacesi, M.D., will join Bristol Myers Squibb as the new Chief Medical Officer and Head of Development, effective August 1, 2025. Dr. Massacesi brings over 20 years of global biopharmaceutical experience, having previously served as Chief Medical Officer at AstraZeneca and Alexion. His extensive background includes overseeing numerous clinical studies and securing regulatory approvals. He will report directly to the CEO and is expected to lead the company’s product development across various therapeutic areas.

Jul 25, 2025 16:43:19